Similar articles

• [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].

  Meyer CH. Meyer CH. Klin Monbl Augenheilkd. 2005 Jan;222(1):62-3. doi: 10.1055/s-2004-813884. Klin Monbl Augenheilkd. 2005. PMID: 15678404 German. No abstract available.
• Clinical trials. Halt of Celebrex study threatens drug's future, other trials.

  Couzin J. Couzin J. Science. 2004 Dec 24;306(5705):2170. doi: 10.1126/science.306.5705.2170a. Science. 2004. PMID: 15618492 No abstract available.
• Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.

  Jugdutt BI. Jugdutt BI. Circulation. 2007 Jan 23;115(3):288-91. doi: 10.1161/CIRCULATIONAHA.106.675306. Circulation. 2007. PMID: 17242292 No abstract available.
• [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].

  Guo ZR. Guo ZR. Yao Xue Xue Bao. 2005 Nov;40(11):967-9. Yao Xue Xue Bao. 2005. PMID: 16499077 Review. Chinese. No abstract available.
• Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?

  Messerli FH, Sichrovsky T. Messerli FH, et al. Am J Cardiol. 2005 Sep 15;96(6):872-3. doi: 10.1016/j.amjcard.2005.05.038. Am J Cardiol. 2005. PMID: 16169380 Review. No abstract available.